Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: A weak and efficient promoter for gene therapy

Molecular Therapy

Volumn 15, Issue 8, 2007, Pages 1487-1494

  Almarza, Elena ^a   Río, Paula ^a   Meza, Nestor W ^a   Aldea, Montserrat ^a   Agirre, Xabier ^b   Guenechea, Guillermo ^a   Segovia, José C ^a   Bueren, Juan A ^a  

^a CIEMAT   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FANCONI ANEMIA GROUP A PROTEIN; LENTIVIRUS VECTOR; VAV PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE TRANSFER; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTO ONCOGENE; SAFETY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INACTIVATION;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DNA METHYLATION; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; PHENOTYPE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-VAV;

SPLEEN FOCUS-FORMING VIRUS;

EID: 34447282985     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300213     Document Type: Article

References (38)

1. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
2. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
3. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
4. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
5. Li, Z, Dullmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
6. Modlich, U, Kustikova, OS, Schmidt, M, Rudolph, C, Meyer, J, Li, Z et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 11: 4235-4246.
7. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
8. Seggewiss, R, Pittaluga, S, Adler, RL, Guenaga, FJ, Ferguson, C, Pilz, IH et al. (2006). Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107: 3865-3867.
9. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
10. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
11. Fehse, B, Kustikova, OS, Bubenheim, M and Baum, C (2004). Pois(s)on - It's a question of dose. Gene Ther 11: 879-881.
12. Kustikova, OS, Wahlers, A, Kuhlcke, K, Stahle, B, Zander, AR, Baum, C et al. (2003). Dose finding with retroviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102: 3934-3937.
13. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13.
14. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Dullmann, J, Kamino, K et al. (2005). Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking. Science 308: 1171-1174.
15. Baum, C, Kustikova, O, Modlich, U, Li, Z and Fehse, B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
16. Bustelo, XR (2000). Regulatory and signaling properties of the Vav family. Mol Cell Biol 20: 1461-1477.
17. Katzav, S, Martin-Zanca, D and Barbacid, M (1989). vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 8: 2283-2290.
18. Ogilvy, S, Elefanty, AG, Visvader, J, Bath, ML, Harris, AW and Adams, JM (1998). Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood 91: 419-430.
19. Dull, T, Zufferey, R, Kelly, M, Mandel, RJ, Nguyen, M, Trono, D et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
20. Meza, NW, Puyet, A, Perez-Benavente, S, Quintana-Bustamante, O, Diez, A, Bueren, JA et al. (2006). Functional analysis of gammaretroviral vector transduction by quantitative PCR. J Gene Med 8: 1097-1104.
21. Antonio Casado, J, Callen, E, Jacome, A, Rio, P, Castella, M, Lobitz, S et al. (2007). A comprehensive strategy for the subtyping of Fanconi Anemia patients: Conclusions from the Spanish Fanconi Anemia research network. J Med Genet 44: 241-249.
22. Taniguchi, T and D'Andrea, AD (2006). The molecular pathogenesis of Fanconi anemia: Recent progress. Blood 107: 4223-4233.
23. Ogilvy, S, Metcalf, D, Gibson, L, Bath, ML, Harris, AW and Adams, JM (1999). Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94: 1855-1863.
24. Almarza, E, Segovia, JC, Guenechea, G, García Gómez, S, Ramírez, A and Bueren, JA (2004). Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. Exp Hematol 32: 360-364.
25. Logan, AC, Haas, DL, Kafri, T and Kohn, DB (2004). Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol 78: 8421-8436.
26. Challita, PM and Kohn, DB (1994). Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 91 2567-2571.
27. Grassi, G, Maccaroni, P, Meyer, R, Kaiser, H, D'Ambrosio, E, Pascale, E et al. (2003). Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24: 1625-1635.
28. Grez, M, Ott, MG, Schmidt, M, Stein, S, Siler, U, Schwarzwaelder, K et al. (2006). Gene Therapy of Chronic Granulomatous Disease. XIV Annual Congress of the European Society of Gene Therapy: 26. European Society of Gene Therapy.
29. Lagresle-Peyrou, C, Yates, F, Malassis-Seris, M, Hue, C, Morillon, E, Garrigue, A et al. (2006). Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: A balance between efficiency and toxicity. Blood 107: 63-72.
30. + cells, but impairs lymphomyeloid differentiation. Blood 101: 1759-1768.
31. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: Therapeutic gene causing lymphoma. Nature 440 1123.
32. + cord blood cells. Hum Gene Ther 14 509-519.
33. Vigna, E, Amendola, M, Benedicenti, F, Simmons, AD, Follenzi, A and Naldini, L (2005). Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol Ther 11: 763-775.
34. Albella, B, Segovia, JC, Guenechea, G, Pragnell, IB and Bueren, JA (1999). Preserved long-term repopulation and differentiation properties of hematopoietic grafts subjected to ex vivo expansion with stem cell factor and interleukin 11. Transplantation 67: 1348-1357.
35. Rio, P, Segovia, JC, Hanenberg, H, Casado, JA, Martinez, J, Gottsche, K et al. (2002). In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood 100: 2032-2039.
36. Varas, F, Bernad, A, Almendral, JM and Bueren, JA (1996). Relevance of myeloablative conditioning in the engraftment of limiting numbers of normal and genetically marked lympho-hematopoietic stem cells. Bone Marrow Transpl 18: 981-989.
37. Guenechea, G, Segovia, JC, Albella, B, Lamana, M, Ramirez, M, Regidor, C et al. (1999). Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood 93: 1097-1105.
38. Roman-Gomez, J, Cordeu, L, Agirre, X, Jimenez-Velasco, A, San Jose-Eneriz, E, Garate, L et al. (2007). Epigenetic regulation of Wnt signaling pathway in acute lymphoblastic leukemia. Blood 109: 3462-3469.